


Technology Advisory Committee A Interests Register

Topic: Sacituzumab govitecan for treating unresectable locally advanced or metastatic triple-negative breast

cancer after 2 or more therapies [ID3942] – TA819

Publication Date: 17/08/2022

Name	Role with NICE	Type of interest	Description of interest	Interest arose	Interest declared	Interest ceased	Comments
Holly Heath and Nicola Tracey	Patient experts	Indirect - financial	In the last 12 months Breast Cancer Now has received funding from the manufacturer Gilead and possible comparator company Roche towards their living with secondary breast cancer support service. Breast Cancer Now also launched a campaign in summer 2021 aimed at Gilead providing early access to Trodelvy following licensing through Project Orbis. More information on this can be found here https://breastcancernow.org/get-involved/campaignus/time-trodelvy	N/A	Holly - 07.09.2021 Nicola - 29.11.2021	N/A	It was agreed that their declarations would not prevent them from providing expert advice to the committee.
Dr Alicia Okines	Clinical expert	Direct - financial	Dr Okines has received Research funding from Pfizer and Roche, Conference support from AstraZeneca,	N/A	08.09.2021	N/A	It was agreed that her declarations would not prevent Dr Okines from



			Lilly, Leo Pharmaceuticals, Daiichi-Sankyo, Advisory Board fees from Roche, Seagen, Astra Zeneca and Daiichi-Sankyo and Speaker fees from Pfizer, Seagen, Lilly, Daiichi-Sankyo, and Gilead. She is also a principal investigator in the TROPICS- 02 trial of Sacituzumab govitecan.				providing expert advice to the committee.
Professor Peter Schmid	Clinical expert	Direct - financial & personal	Professor Schmid has received honorarium for advisory and research boards from AstraZeneca, Bayer, Boehringer Ingelheim, Celgene, Eisai, Gilead, Merck, MSD, Novartis, Pfizer, Puma, and Roche. His institution has received grants and funding from Astellas, AstraZeneca, Genentech, Novartis, Oncogenex, Roche, Medivation and his spouse is an employee of Roche.	N/A	02.09.2021	N/A	It was agreed that his declarations would not prevent Professor Schmid from providing expert advice to the committee.